How Molecular Biomarkers Have Impacted Cancer Treatment

Geoff Oxnard, MD
Thoracic Oncologist, Dana-Farber Cancer Institute,
Associate Professor of Medicine, Harvard Medical School,
Boston, MA
Lauren Ritterhouse, MD, PhD
Molecular Pathologist and Co-Director
Molecular Diagnostics and Clinical Genomics Laboratories, University of Chicago
Chicago, IL
Drs Geoffrey Oxnard and Lauren Ritterhouse discuss the challenges and opportunities of precision medicine and molecular biomarkers in their clinical practice from an oncologist’s and a pathologist’s perspective.
Related Articles
Reimbursement Challenges and Solutions with Molecular Biomarker Testing
Geoff Oxnard, MD, Lauren Ritterhouse, MD, PhD
|
Video Library
Drs. Geoffrey Oxnard and Lauren Ritterhouse consider the current landscape of reimbursement for molecular biomarker testing, the need to run FDA-approved tests, and the role of CMS and local Medicare providers in testing reimbursement.
Financial Constraints to Molecular Biomarker Testing
David L Rimm, MD, PhD, Roy S. Herbst, MD, PhD
|
Video Library
Drs. David Rimm and Roy Herbst discuss the challenges of reimbursement by payers and the costs to pathology department of molecular biomarker testing, especially immunohistochemistry and DNA testing.
A New Day for Patients with Melanoma: Raising Awareness About Prevention and the Latest Treatment Options
Kristin Siyahian
|
September 2018 Vol 9, No 9
An interview with Stephanie Whitten of Meredith’s Mission for Melanoma and Matthew Fox, MD, of The University of Texas
Last modified: July 30, 2018

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code